Wuxi AppTec Co's book value per share for the quarter that ended in Mar. 2024 was ¥18.97.
During the past 12 months, Wuxi AppTec Co's average Book Value Per Share Growth Rate was 13.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 18.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 26.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Wuxi AppTec Co was 59.10% per year. The lowest was 18.70% per year. And the median was 35.20% per year.
Wuxi AppTec Co's current price is ¥44.90. Its book value per share for the quarter that ended in Mar. 2024 was ¥18.97. Hence, today's PB Ratio of Wuxi AppTec Co is 2.37.
During the past 10 years, the highest P/B Ratio of Wuxi AppTec Co was 20.80. The lowest was 2.22. And the median was 7.80.
Good Sign:
Wuxi AppTec Co Ltd stock PB Ratio (=2.42) is close to 10-year low of 2.22
Wuxi AppTec Co Book Value per Share Historical Data
The historical data trend for Wuxi AppTec Co's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Wuxi AppTec Co's Book Value per Share
For the Diagnostics & Research subindustry, Wuxi AppTec Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co's PB Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's PB Ratio falls into.
Wuxi AppTec Co Book Value per Share Calculation
Wuxi AppTec Co's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Wuxi AppTec Co (SHSE:603259) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Wuxi AppTec Co Book Value per Share Related Terms
Thank you for viewing the detailed overview of Wuxi AppTec Co's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603259 has been successfully added to your 